Diferido
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
1,73 USD | -1,14 % | 0,00 % | +17,69 % |
13/03 | Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024 | |
13/03 | Spero Therapeutics, Inc. informa de los resultados del cuarto trimestre finalizado el 31 de diciembre de 2023 | CI |
Resumen de negocios
Número de empleados: 46
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Novel Treatments for Multi-drug Resistant Bacterial Infections
100,0
%
| 54 | 100,0 % | 104 | 100,0 % | +93,95 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 54 | 100,0 % | 104 | 100,0 % | +93,95 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Satyavrat Shukla
CEO | Chief Executive Officer | 52 | 04/01/21 |
Ankit Mahadevia
FOU | Founder | 43 | 01/04/13 |
Esther Rajavelu
DFI | Director of Finance/CFO | 46 | 06/11 |
Kamal Hamed
CTO | Chief Tech/Sci/R&D Officer | 63 | 15/09/22 |
Angela Talley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Timothy Keutzer
COO | Chief Operating Officer | 56 | - |
Ted Jenkins
IRC | Investor Relations Contact | - | - |
James P. Brady
HRO | Human Resources Officer | - | - |
Ian A. Critchley
PRN | Corporate Officer/Principal | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Frank Thomas
BRD | Director/Board Member | 54 | 01/07/17 |
John Pottage
BRD | Director/Board Member | 71 | 14/08/18 |
Scott Jackson
BRD | Director/Board Member | 59 | 16/04/20 |
Milind Deshpande
FOU | Founder | 68 | 01/01/14 |
Director/Board Member | 61 | 01/09/15 | |
Ankit Mahadevia
FOU | Founder | 43 | 01/04/13 |
Cynthia Smith
BRD | Director/Board Member | 55 | 19/03/19 |
Director/Board Member | 53 | 11/10/21 | |
Satyavrat Shukla
CEO | Chief Executive Officer | 52 | 04/01/21 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 53 869 139 | 42 904 616 ( 79,65 %) | 0 | 79,65 % |
Información de la empresa
Spero Therapeutics, Inc.
675 Massachusetts Avenue 14th floor
02139, Cambridge
+857 242 1600
http://www.sperotherapeutics.comSector
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+17,69 % | 94,27 M | |
+2,71 % | 108 mil M | |
+9,80 % | 104 mil M | |
+6,58 % | 23,66 mil M | |
-12,47 % | 22,1 mil M | |
-3,29 % | 19,71 mil M | |
-35,36 % | 18,2 mil M | |
-13,16 % | 16,19 mil M | |
+4,37 % | 13,72 mil M | |
+34,71 % | 12,22 mil M |
- Bolsa
- Acciones
- Acción Spero Therapeutics, Inc. - Nasdaq
- Empresa Spero Therapeutics, Inc.